Restart Life Sciences Corp. (NMLSD)
- Previous Close
0.0000 - Open
0.1020 - Bid 0.0600 x --
- Ask 0.1000 x --
- Day's Range
0.1020 - 0.1020 - 52 Week Range
0.0202 - 0.1500 - Volume
1,747 - Avg. Volume
9,276 - Market Cap (intraday)
951,468 - Beta (5Y Monthly) 0.82
- PE Ratio (TTM)
-- - EPS (TTM)
-0.1400 - Earnings Date May 27, 2025 - Jun 2, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Restart Life Sciences Corp., through its subsidiaries, operates as a biotechnology company worldwide. It engages in developing diagnostics and psilocybin-based therapeutics for the treatment of neuroinflammatory disorders, including autism spectrum disorder and fragile X syndrome. The company was formerly known as Nova Mentis Life Science Corp. and changed its name to Restart Life Sciences Corp. in November 2024. Restart Life Sciences Corp. was incorporated in 2004 and is based in Vancouver, Canada.
www.restartlife.coRecent News: NMLSD
View MorePerformance Overview: NMLSD
Trailing total returns as of 4/29/2025, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index (^GSPTSE) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NMLSD
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NMLSD
View MoreValuation Measures
Market Cap
1.20M
Enterprise Value
1.13M
Trailing P/E
6.39
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-219.74%
Return on Equity (ttm)
--
Revenue (ttm)
-28.35k
Net Income Avi to Common (ttm)
15.05k
Diluted EPS (ttm)
-0.1400
Balance Sheet and Cash Flow
Total Cash (mrq)
250.59k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-200.21k